Evaluation of performance of the GENECUBE assay for rapid molecular identification of Staphylococcus aureus and methicillin resistance in positive blood culture medium.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2019
Historique:
received: 20 11 2018
accepted: 03 07 2019
entrez: 17 7 2019
pubmed: 17 7 2019
medline: 4 3 2020
Statut: epublish

Résumé

Rapid identification of causative agents from positive blood culture media is a prerequisite for the timely targeted treatment of patients with sepsis. The GENECUBE (TOYOBO Co., Ltd.) is a novel, fully-automated gene analyzer that can purify DNAs and amplify target DNAs. In this study, we evaluated the ability of two newly developed GENECUBE assays to directly detect the nuc and mecA genes in blood culture medium; nuc is specific to Staphylococcus aureus, and mecA indicates methicillin resistance. We examined 263 positive blood culture samples taken at three hospitals from patients suspected of having staphylococcal bacteremia. The results were then compared with those obtained using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry, antimicrobial susceptibility testing (Microscan system or Dry-plate EIKEN), and sequencing analysis. The GENECUBE assays had sensitivity and specificity of 100% in detecting both S. aureus and methicillin resistance in positive blood culture. The turnaround time of the examination was evaluated for 36 positive blood culture samples. The time between the initiation of incubation and completion of the GENECUBE examination was 23 h (interquartile range: IQR 21-37 h); the time between reporting of Gram stain examination and completion of the GENECUBE examination was 52 min (IQR 48-62 min). These findings show that the GENECUBE assays significantly reduce the assay time with no loss of sensitivity or specificity.

Identifiants

pubmed: 31310615
doi: 10.1371/journal.pone.0219819
pii: PONE-D-18-33352
pmc: PMC6634395
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0219819

Déclaration de conflit d'intérêts

Hiroyasu Sugimoto and Yosuke Kawashima are employees of TOYOBO CO., LTD. Shigeyuki Notake received a lecture fee from TOYOBO CO., LTD. Hiromichi Suzuki received a lecture fee and advisory fee from TOYOBO CO., LTD. No additional external funding was received for this study. This does not alter our adherence to PLoS ONE policies on sharing data and materials.

Références

Microb Pathog. 2017 Feb;103:80-86
pubmed: 27894963
J Clin Microbiol. 1992 Jul;30(7):1654-60
pubmed: 1629319
Clin Microbiol Rev. 2014 Oct;27(4):647-64
pubmed: 25278570
J Clin Microbiol. 2015 Nov;53(11):3630-2
pubmed: 26292311
Tohoku J Exp Med. 2018;246(4):225-231
pubmed: 30541996
J Microbiol Immunol Infect. 2010 Aug;43(4):347-9
pubmed: 20688297
J Clin Microbiol. 2010 May;48(5):1584-91
pubmed: 20237093
Clin Microbiol Infect. 2018 Feb;24(2):125-132
pubmed: 28698037
Ann Lab Med. 2017 Jan;37(1):39-44
pubmed: 27834064
Clin Infect Dis. 2004 Aug 1;39(3):309-17
pubmed: 15306996
J Antimicrob Chemother. 2017 Nov 1;72(11):3191-3198
pubmed: 28961942
Appl Environ Microbiol. 2001 Jul;67(7):3122-6
pubmed: 11425731
J Clin Microbiol. 2013 Nov;51(11):3579-84
pubmed: 23966484
Mol Diagn Ther. 2018 Dec;22(6):737-747
pubmed: 30259422
J Clin Microbiol. 2016 Mar;54(3):687-98
pubmed: 26739158
Jpn J Antibiot. 2016 Aug;69(4):291-298
pubmed: 30226955
Clin Infect Dis. 2003 Jun 1;36(11):1418-23
pubmed: 12766837
PLoS One. 2017 Nov 8;12(11):e0187688
pubmed: 29117261
Food Res Int. 2012 Jul 1;47(2):166-173
pubmed: 22778501
Diagn Microbiol Infect Dis. 2019 Feb;93(2):120-124
pubmed: 30241971
Clin Microbiol Infect. 2018 Sep;24(9):944-955
pubmed: 29787889
Clin Infect Dis. 2015 Aug 1;61(3):361-7
pubmed: 25900170
Trends Microbiol. 2014 Jan;22(1):42-7
pubmed: 24331435
FEMS Immunol Med Microbiol. 2008 Nov;54(2):157
pubmed: 18811719
J Clin Microbiol. 2015 Mar;53(3):804-9
pubmed: 25540397
J Infect Dis. 2008 Aug 1;198(3):336-43
pubmed: 18522502
Clin Infect Dis. 2007 Jan 15;44(2):190-6
pubmed: 17173215
Clin Infect Dis. 2009 May 15;48 Suppl 4:S254-9
pubmed: 19374581
Arch Intern Med. 2003 Sep 22;163(17):2066-72
pubmed: 14504120
Anal Chem. 2009 Jul 15;81(14):5678-85
pubmed: 19530673
J Clin Microbiol. 2012 Nov;50(11):3604-8
pubmed: 22933602
J Clin Microbiol. 2012 Jun;50(6):2056-8
pubmed: 22493335
J Clin Microbiol. 1990 Mar;28(3):495-503
pubmed: 1691208
Lancet. 2006 Sep 2;368(9538):874-85
pubmed: 16950365
J Clin Microbiol. 2015 Dec;53(12):3900-4
pubmed: 26400789
PLoS Med. 2013;10(7):e1001478
pubmed: 23843749
J Clin Microbiol. 1991 Oct;29(10):2240-4
pubmed: 1939577
J Infect Chemother. 2015 Dec;21(12):849-56
pubmed: 26433422
Microb Pathog. 2016 Dec;101:56-67
pubmed: 27836760

Auteurs

Yukio Hida (Y)

Department of Clinical Laboratory, University of Fukui Hospital, Yoshida-gun, Fukui, Japan.

Keiichi Uemura (K)

Department of Clinical Laboratory, Chutoen General Medical Center, Kakegawa, Shizuoka, Japan.

Hiroyasu Sugimoto (H)

Tsuruga Institute of Biotechnology, TOYOBO Co., Ltd., Tsuruga, Fukui, Japan.

Yosuke Kawashima (Y)

Diagnostic System Department, TOYOBO Co., Ltd., Osaka, Osaka, Japan.

Norito Koyanagi (N)

Department of Clinical Laboratory, Chutoen General Medical Center, Kakegawa, Shizuoka, Japan.

Shigeyuki Notake (S)

Department of Clinical Laboratory, Tsukuba Medical Center Hospital, Tsukuba, Ibaraki, Japan.

Yusaku Akashi (Y)

Department of Clinical Laboratory Medicine, Tsukuba Medical Center Hospital, Tsukuba, Ibaraki, Japan.
Division of Infectious Disease, Department of Medicine, Tsukuba Medical Center Hospital, Tsukuba, Ibaraki, Japan.

Shohei Sakaguchi (S)

Department of Clinical Laboratory, University of Fukui Hospital, Yoshida-gun, Fukui, Japan.

Hideki Kimura (H)

Department of Clinical Laboratory, University of Fukui Hospital, Yoshida-gun, Fukui, Japan.

Hiromichi Suzuki (H)

Department of Clinical Laboratory Medicine, Tsukuba Medical Center Hospital, Tsukuba, Ibaraki, Japan.
Division of Infectious Disease, Department of Medicine, Tsukuba Medical Center Hospital, Tsukuba, Ibaraki, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH